Abstract Number: 2666 • 2017 ACR/ARHP Annual Meeting
The Clinical Utility of Flow-Mediated Dilation in Systemic Sclerosis Digital Ulcer Assessment
Background/Purpose: Systemic sclerosis (SSc, scleroderma) patients can have the end-stage vasculopathy manifestation of a digital ulcer (DU). Brachial artery flow mediated dilation (FMD) is an…Abstract Number: 2667 • 2017 ACR/ARHP Annual Meeting
The Association between Two Non-Invasive Methods for the Assessment of Severity of Gastrointestinal Involvement and Malnutrition in Systemic Sclerosis: Self-Reported Questionnaires and Nail Fold Video-Capillaroscopy
Background/Purpose: Gastrointestinal (GI) system involvement is commonly seen in sytemic sclerosis (SSc) up to 90% of the patients during disease duration and one of the…Abstract Number: 2668 • 2017 ACR/ARHP Annual Meeting
Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients
Background/Purpose: Gastrointestinal tract (GIT) involvement in systemic sclerosis (SSc) is the most common internal organ involvement. Among the few validated patient-reported outcome measures for GI…Abstract Number: 2669 • 2017 ACR/ARHP Annual Meeting
Microvascular Flow Assessed By Dynamic Optical Coherence Tomography: First Non-Invasive Quantitative Outcome Measure of Microvascular Disease in Systemic Sclerosis
Background/Purpose: Virtual skin biopsy by Optical Coherence Tomography (OCT) has been proposed as quantitative outcome measure of fibrosis in Systemic Sclerosis (SSc). Dynamic OCT (D-OCT)…Abstract Number: 2670 • 2017 ACR/ARHP Annual Meeting
Trigeminal Neuralgia in Systemic Sclerosis
Background/Purpose: Trigeminal neuralgia (TN) is characterized by pain and spasms affecting one or more divisions of the fifth cranial nerve. Of note, TN is one…Abstract Number: 2671 • 2017 ACR/ARHP Annual Meeting
Bosentan in Scleroderma Renal Crisis: A National Open Label Prospective Study
Background/Purpose: Scleroderma renal crisis (SRC), a life-threatening complication of systemic sclerosis (SSc), arises despite therapy combining an angiotensin-converting–enzyme inhibitor (AECI) and/or dialysis. Endothelin-1 (ET-1), a…Abstract Number: 2672 • 2017 ACR/ARHP Annual Meeting
Perceived Barriers to Mental Health Care Among Patients with Systemic Sclerosis: A Qualitative Study
Background/Purpose: Systemic Sclerosis (SSc) is characterized by disfigurement, morbidity, and increased mortality. The diagnosis carries significant psychosocial impact on patients, and many suffer with depression,…Abstract Number: 2673 • 2017 ACR/ARHP Annual Meeting
Real-Life Treatment Strategies for Systemic Sclerosis According to Experts
Background/Purpose:Second line treatment options for Systemic Sclerosis (SSc) are limited, and scarce data are available for choosing the order of treatment. The aim of this…Abstract Number: 2674 • 2017 ACR/ARHP Annual Meeting
The Association between the Extent of Skin Thickness and Organ Involvement, Function and Quality of Life in Early Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: To estimate whether severity of skin thickness is associated with disease severity, function, quality of life (QoL) and progression of internal organ involvement over…Abstract Number: 2675 • 2017 ACR/ARHP Annual Meeting
Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease once characterized by high mortality rates now with better outcomes. Pulmonary disease has overtaken renal failure…Abstract Number: 2676 • 2017 ACR/ARHP Annual Meeting
Reduction of Dlco and FVC in Patients with GERD and Systemic Sclerosis
Background/Purpose: Esophageal involvement is common in Systemic Sclerosis (SSc). It is estimated to occur in 70-90% of patients. Esophageal motor dysfunction is characterized by hypotonia…Abstract Number: 2677 • 2017 ACR/ARHP Annual Meeting
Impact of Rheumatologic Evaluation and Serologic Testing on Patients with Fibrotic Interstitial Lung Disease: A Single Center Retrospective Experience
Background/Purpose: The evaluation of patients who develop interstitial lung disease (ILD) includes an assessment for underlying rheumatic disease or connective tissue disease (CTD). Delineating a…Abstract Number: 2678 • 2017 ACR/ARHP Annual Meeting
Comparison of Scleroderma Associated Isolated Pulmonary Arterial Hypertension and Pulmonary Hypertension with Concomitant Interstitial Lung Disease
Background/Purpose: Relatively little data exist in the literature to characterize the differences between patients with scleroderma-associated isolated pulmonary arterial hypertension (SSc-PAH, WHO Group 1) and…Abstract Number: 2679 • 2017 ACR/ARHP Annual Meeting
Mortality Is Increased in Scleroderma Associated Pulmonary Arterial Hypertension Patients with Younger Age, Lower Systolic Blood Pressure, and Lower Cardiac Index, but Not in Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Survival in scleroderma associated pulmonary arterial hypertension (SSc-PAH) is known to be significantly worse compared to that in idiopathic pulmonary arterial hypertension (iPAH). However,…Abstract Number: 2680 • 2017 ACR/ARHP Annual Meeting
Analysis of Prognostic Determinants of Scleroderma-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Systemic sclerosis (SSc) associated pulmonary arterial hypertension (SSc-PAH) is a serious and often life-threatening complication of SSc. Perhaps the most important enigma in the…
